Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L

Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L

Since the outbreak of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), public health worldwide has been greatly threatened. The development of an effective treatment for this infection is crucial and urgent but is hampered by the incompl...

Full description

Bibliographic Details
Main Authors: Fei Yu, Ting Pan, Feng Huang, Ruosu Ying, Jun Liu, Huimin Fan, Junsong Zhang, Weiwei Liu, Yingtong Lin, Yaochang Yuan, Tao Yang, Rong Li, Xu Zhang, Xi Lv, Qianyu Chen, Anqi Liang, Fan Zou, Bingfeng Liu, Fengyu Hu, Xiaoping Tang, Linghua Li, Kai Deng, Xin He, Hui Zhang, Yiwen Zhang, Xiancai Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Microbiology
Subjects:
teicoplanin
SARS-CoV-2
spike
cathepsin L
viral entry
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2022.884034/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2022.884034/full

Similar Items